PRecISion Medicine for Children With Cancer

Active, not recruitingOBSERVATIONAL
Enrollment

550

Participants

Timeline

Start Date

September 5, 2017

Primary Completion Date

August 31, 2028

Study Completion Date

December 31, 2032

Conditions
Childhood CancerChildhood Solid TumorChildhood Brain TumorChildhood LeukemiaRefractory CancerRelapsed Cancer
Interventions
DIAGNOSTIC_TEST

Molecular profiling and drug testing

"1. Laboratory analysis including:~ A. Tumour molecular profiling: targeted whole exon variant analysis, whole genome (DNA) and transcriptome (RNA) sequencing, methylation analysis, proteomics analysis, immunohistochemistry B. In vitro high-throughput drug sensitivity testing C. In vivo drug testing using patient-derived xenograft (PDX) models D. Liquid biopsies~2. Multi-disciplinary Tumour Board case discussion~3. Recommendation of personalised therapy"

Trial Locations (8)

2031

Sydney Children's Hospital, Randwick, Sydney

2145

The Children's Hospital at Westmead, Sydney

2305

John Hunter Children's Hospital, Newcastle

3052

Royal Children's Hospital, Melbourne

3168

Monash Children's Hospital, Melbourne

4101

Queensland Children's Hospital, Brisbane

5006

Women's and Children's Hospital, Adelaide

6008

Perth Children's Hospital, Perth

Sponsors
All Listed Sponsors
collaborator

Children's Cancer Institute Australia

UNKNOWN

collaborator

Australian & New Zealand Children's Haematology/Oncology Group

OTHER

collaborator

Garvan Institute of Medical Research

OTHER

collaborator

German Cancer Research Center

OTHER

lead

Sydney Children's Hospitals Network

OTHER

NCT03336931 - PRecISion Medicine for Children With Cancer | Biotech Hunter | Biotech Hunter